<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Horizon offers update on TED treatment option

CU Department of Ophthalmology Professor Prem Subramanian, MD, PhD, discusses a double-masked randomized placebo controlled trial of the use of TEPEZZA in patients with a much longer duration of thyroid eye disease than those who are enrolled in the phase 2 and phase 3 studies that lead to FDA approval.

Topics: Press Coverage

Related Stories